Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.74 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.53 |
| ▸ | EML4 | Q9HC35 | 2/20 | 0.52 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24662609 | 1.00 | EGFR (0.74) | EGFRALKEML4ERBB3PTK2 | |
| SCHEMBL29936740 | 0.93 | EGFR (0.84) | EGFRALKEML4ERBB3PTK2 | |
| SCHEMBL24663098 | 0.93 | EGFR (0.84) | EGFRALKEML4ERBB3PTK2 | |
| SCHEMBL27004241 | 0.91 | EGFR (0.71) | EGFRALKEML4ERBB3PTK2 | |
| SCHEMBL27004222 | 0.90 | EGFR (0.60) | EGFRALKEML4ERBB3 | |
| SCHEMBL29936610 | 0.84 | EGFR (0.51) | EGFRALKEML4ERBB3 | |
| SCHEMBL24662651 | 0.84 | EGFR (0.51) | EGFRALKEML4ERBB3 | |
| SCHEMBL24663094 | 0.82 | EGFR (0.50) | EGFRALK | |
| SCHEMBL29936795 | 0.82 | EGFR (0.50) | EGFRALK | |
| SCHEMBL24663025 | 0.82 | EGFR (0.54) | EGFRALKEML4ERBB3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022191664-A1 | NOVEL PYRIMIDINE DERIVATIVE SHOWING INHIBITION EFFECT ON GROWTH OF CANCER CELLS | 주식회사 온코빅스 | 2022-09-15 | — | — | WO | claimed |
| WO-2022191664-A1 | NOVEL PYRIMIDINE DERIVATIVE SHOWING INHIBITION EFFECT ON GROWTH OF CANCER CELLS | 주식회사 온코빅스 | 2022-09-15 | — | — | WO | disclosed |